These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1835587)

  • 1. Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer.
    Falkson CI; Falkson HC; Falkson G
    Eur J Cancer; 1991; 27(10):1208-11. PubMed ID: 1835587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAF and nasal buserelin in the treatment of premenopausal women with metastatic breast cancer.
    Falkson G; Falkson HC
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):737-41. PubMed ID: 2497019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide, doxorubicin and fluorouracil (CAF) plus depo-buserelin in the treatment of premenopausal women with metastatic breast cancer.
    Falkson CI; Falkson HC; Falkson G
    Ann Oncol; 1992 Dec; 3(10):849-53. PubMed ID: 1286048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen.
    Delrio G; De Placido S; Pagliarulo C; d'Istria M; Fasano S; Marinelli A; Citarella F; De Sio L; Contegiacomo A; Iaffaioli RV
    Tumori; 1986 Feb; 72(1):53-61. PubMed ID: 3754071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer.
    Bianco AR; De Placido S; Pagliarulo C; Fasano S; D'Istria M; De Sio L; Ricciardi I; Delrio G
    Chemioterapia; 1985 Jun; 4(3):252-5. PubMed ID: 3839720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer.
    Klijn JG; de Jong FH
    Lancet; 1982 May; 1(8283):1213-6. PubMed ID: 6122975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DTC chemotherapy regimen is associated with higher incidence of premature ovarian failure in women of reproductive age with breast cancer.
    Long JP; Wan F; Zhang F; Zhou J; Don LF
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1087-92. PubMed ID: 27049261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer.
    Walker KJ; Turkes A; Williams MR; Blamey RW; Nicholson RI
    J Endocrinol; 1986 Nov; 111(2):349-53. PubMed ID: 2947964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
    Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
    J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy.
    Samaan NA; deAsis DN; Buzdar AU; Blumenschein GR
    Cancer; 1978 Jun; 41(6):2084-7. PubMed ID: 418867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide.
    Doberauer C; Niederle N; Schmidt CG
    Cancer; 1988 Aug; 62(3):474-8. PubMed ID: 3134119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer.
    Walker KJ; Walker RF; Turkes A; Robertson JF; Blamey RW; Griffiths K; Nicholson RI
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):651-4. PubMed ID: 2523808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum luteinizing hormone, follicle-stimulating hormone and oestradiol pattern in women undergoing pituitary suppression with different gonadotrophin-releasing hormone analogue protocols for assisted reproduction.
    Manna C; Rahman A; Sbracia M; Pappalardo S; Mohamed EI; Linder R; Nardo LG
    Gynecol Endocrinol; 2005 Apr; 20(4):188-94. PubMed ID: 16019360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer.
    Robertson JF; Walker KJ; Nicholson RI; Blamey RW
    Br J Surg; 1989 Dec; 76(12):1262-5. PubMed ID: 2532556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study).
    Bianco AR; Rosso R; Calabresi F; Fiorentino M; Lopez M; Sismondi PG; Lenti R; Fosser V; De Placido S; Perrone F
    Eur J Gynaecol Oncol; 1991; 12(6):429-37. PubMed ID: 1839730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer.
    Rose DP; Davis TE
    Lancet; 1977 Jun; 1(8023):1174-6. PubMed ID: 68275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
    Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
    Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.